Skip to main content

Table 4 Estimates of key quantities characterizing the performance of the proposed two test workflow when 1-year or 3-year occurrences of hazardous events (HE) are taken into account along with 6-month angiographic restenosis results

From: Stratification of coronary artery disease patients for revascularization procedure based on estimating adverse effects

Estimated quantity

1- year HE

3- years HE

Mean

95% CI

Mean

95% CI

\( \widehat{P}\left(\mathrm{sBMS}\right) \)

9.7

3.6 – 18.0

5.0

2.6 – 9.5

\( \widehat{P}\left(\mathrm{sDES}\right) \)

81.8

74.3 – 87.5

85.3

81.4 – 87.7

\( \widehat{P}\left(\mathrm{sCABG}\right) \)

8.5

7.5 – 9.0

9.6

7.8 – 10.6

\( \widehat{P}\left(\mathrm{Restenosis}\left|\mathrm{sBMS}\right.\right) \)

0.1

0.0 – 0.0

0.0

0.0 – 0.0

\( \tilde{P}\left(\mathrm{Restenosis}\left|\mathrm{sDES}\right.\right) \)

7.6

6.7 – 7.9

7.0

6.1 – 7.5

\( \widehat{P}\left(\mathrm{Restenosis}\right) \)

6.4

5.5 – 6.9

6.2

5.3 – 6.6

\( \tilde{P}\left(\mathrm{Hazard}\left|\mathrm{sBMS}\right.\right) \)

0.0

0.0 – 0.0

1.5

0.0 – 16.7

\( \widehat{P}\left(\mathrm{Hazard}\left|\mathrm{sDES}\right.\right) \)

3.2

2.1 – 3.5

8.2

7.2 – 9.5

\( \widehat{P}\left(\mathrm{Hazard}\right) \)

3.3

2.5 – 3.8

7.9

6.9 – 9.5

Baseline estimate for P(Adverse effect)

14.1

12.6 – 14.5

18.8

17.6 – 19.6

Proposed estimate for P(Adverse effect)

9.7

8.3 – 10.6

14.1

12.4 – 15.6

ΔP(Adverse effect)

4.4

3.5 – 5.4

4.7

3.4 – 5.5

  1. The acronyms sBMS, sDES and sCABG denote that the proposed model suggested treatment with bare-metal stents, drug-eluting stents or coronary artery bypass grafting, respectively. Baseline refers to predominant treatment with drug-eluting stents as described in section “Baseline Effectiveness and Costs”.